TCT 2024 Late-Breaking Science Collection
Published: 17 October 2024
-
Views:
2697
-
Likes:
7
-
Views:
2697
-
Likes:
7
-
Up Next -
5m 36sPart 2 | Session 4 MATTERHORN: Transcatheter Repair Versus Surgery in Mitral Regurgitation -
3m 34sPart 2 | Session 5 INFINITY-SWEDEHEART: DynamX Bioadaptor in Patients with Complex Lesions -
3m 43s -
3m 33s -
3m 56s -
6m 32s
-
6m 24sPart 3 | Session 1 5 Trials That Will Change My Practice with Dr Mirvat Alasnag -
5m 1sPart 3 | Session 2 2 Trials That Will Change My Practice with Dr Sahil Parikh
-
38m 7sPart 1 View from the Thoraxcenter: TCT 24 Late-breaking Preview Nicolas M Van Mieghem, Joost Daemen
-
7m 10sPart 2 | Session 1 SIRONA: Sirolimus- vs. Paclitaxel-Coated Balloon Angioplasty in the Femoropopliteal Artery Ulf Teichgräber
-
4m 10sPart 2 | Session 2 TAVR UNLOAD: Transcatheter Aortic Valve Replacement in Patients with Heart Failure and Moderate Aortic Stenosis Nicolas M Van Mieghem
Overview
Keep informed with our video collection unveiling data from the Transcatheter Cardiovascular Therapeutics Conference in Washington. With expert insights on late-breaking trials and critical findings, you won't want to miss our #TCT24 coverage.
- For practice-focused reviews of the most anticipated trials, watch our recurring View From the Thoraxcenter series, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL).
- Our short Expert Interviews with select faculty offer focused data analysis and take-home messages for practice.
- To delve deeper into insights on the most pertinent trials, catch our Highlights.
Dive into the latest cardiology research with our upcoming TCT Conference coverage.
More from this programme
Part 1
View From the Thoraxcenter: What's Hot at TCT 24?
Part 2
Expert Interviews
About the episode
TCT Conference 2024 - Clinical outcomes of early intervention in patients with asymptomatic aortic stenosis (AS) did not impact the composite primary outcome of all cause mortality and unplanned AS related hospitalisation.
Dr Marc Dweck (University of Edinburgh, Edinburgh, UK) joins us in this short interview filmed onsite at TCT Conference to discuss the findings from EVOLVED (NCT03094143; University of Edinburgh).
EVOLVED is a multicenter, prospective, controlled trial, where patients with asymptomatic severe AS were screened across sites to measure high-sensitivity troponin to evaluate risk of left ventricular decompensation. Patients with mid wall fibrosis (heart scarring) are randomized to receive either early surgical intervention or routine care. Participants with no mid-wall fibrosis are randomized to routine care with study follow up, or without study follow up. 208 patients were enrolled in the trial and were followed-up at study completion, which is expected at 2.75 years.
The primary outcome measure, a composite of the first event of all-cause mortality or unplanned AS-related hospitalisation, was not met.
Interview Questions:
1. What is the reasoning behind the trial?
2. What was the study design and patient population for EVOLVED?
3. What were the key findings and take-home messages?
4. What further research is needed, and what are the next steps?
Recorded at TCT Conference in Washington, 2024.
Editors: Yazmin Sadik, Jordan Rance
Video Specialist: David Ben-Harosh, Oliver Miles
Support: This is an independent interview produced by Radcliffe Cardiology.
Faculty Biographies
Marc Dweck
Professor of Clinical Cardiology
Professor Marc Dweck is the Professor of Clinical Cardiology and Consultant at the University of Edinburgh, UK. He is an EACVI Board Member with clinical interests in multi-modality imaging and cardiac device implantation His research program is centred around the use of multi-modality imaging (echo, CT, CMR, PET) to improve our understanding of cardiovascular pathophysiology and ultimately to improve patient assessment, care and outcomes. In particular he has focused on coronary atherosclerosis, aortic stenosis and cardiomyopathy. He has published in many of the leading medical and cardiovascular journals and is the recipient of numerous national and international awards (e.g. Michael Davies Award; Sir Jules Thorn Award; BHF Outstanding Investigator Award, Parmley Prize JACC). He is currently the Chief Investigator of two ongoing RCTs trials of novel therapeutic strategies in aortic stenosis (SALTIRE 2 NCT02132026 & EVOLVED NCT03094143).
Comments